Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response

about

Therapeutic approaches to diabetic nephropathy--beyond the RAS.Sex-dependent differences in renal angiotensinogen as an early marker of diabetic nephropathy.

P2860

Q38209811-3935269B-3623-4BEB-BF1E-E21968475673 Q41663017-513A2D7C-399E-40CD-B17E-C95E7A180F56

P2860

Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response

Item

http://www.wikidata.org/entity/Q57214519

description

article

@en

im Jahr 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2011

@uk

name

Stopping renin-angiotensin sys ...... isease: predictors of response

@en

Stopping renin-angiotensin sys ...... isease: predictors of response

@nl

type

Item

label

Stopping renin-angiotensin sys ...... isease: predictors of response

@en

Stopping renin-angiotensin sys ...... isease: predictors of response

@nl

prefLabel

Stopping renin-angiotensin sys ...... isease: predictors of response

@en

Stopping renin-angiotensin sys ...... isease: predictors of response

@nl

P1476

Stopping renin-angiotensin sys ...... isease: predictors of response

@en

P2093

Aimun K Ahmed

http://www.w3.org/2001/XMLSchema#string

Anderson Roman Gonçalves

http://www.w3.org/2001/XMLSchema#string

Arif Khwaja

http://www.w3.org/2001/XMLSchema#string

Meguid El Nahas

http://www.w3.org/2001/XMLSchema#string

Mohsen El Kossi

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring the accuracy of diagnostic systems

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Efficacy and safety of benazepril for advanced chronic renal insufficiency.

The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease

Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Age, race, diabetes, blood pressure, and mortality among hemodialysis patients.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.

Intensive blood-pressure control in hypertensive chronic kidney disease

P304

c348-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000330289

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22135795

http://www.w3.org/2001/XMLSchema#string

Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response

about

P2860

P2860

Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698